Development of AAV-AIBP for neuroprotection in glaucoma

用于青光眼神经保护的 AAV-AIBP 的开发

基本信息

  • 批准号:
    10680277
  • 负责人:
  • 金额:
    $ 77.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-15 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

Glaucoma is a leading cause of blindness worldwide. Emerging evidence suggests that glia-neuroinflammation is a critical element driving retinal ganglion cell (RGC) death and optic nerve degeneration in the pathogenesis of glaucoma. Gene polymorphisms in toll-like receptor-4 (TLR4, inflammatory receptor) and ATP-binding cassette transporter A1 (ABCA1, cellular cholesterol transporter) are linked to the risk of primary open-angle glaucoma. Our studies demonstrated increased TLR4 and reduced ABCA1 expression in RGCs and glia in human glaucomatous retina. We identified the secreted apoA-I binding protein (AIBP; gene APOA1BP) as a key regulator of cellular cholesterol metabolism, which controls TLR4 activation via ABCA1-dependent cholesterol depletion from TLR4 occupied lipid rafts in inflammatory and activated cells. Similar to ABCA1, AIBP expression was reduced, while cholesterol levels and inflammatory markers increased in human and mouse glaucomatous retinas. Apoa1bp-/- mice had compromised visual acuity and compared to wild type, had increased retinal TLR4 and IL-1β expression, augmented microglial activation, and increased RGC death in response to elevated intraocular pressure (IOP). These findings support the rationale for restoration of AIBP expression in the retina to provide sustained neuroprotection in patients with glaucoma. In preliminary studies, adeno-associated virus (AAV)-AIBP protected RGCs and ameliorated visual dysfunction in experimental mouse models of glaucoma. In addition, recombinant AIBP protein promoted mitochondrial function as well as inhibited inflammatory responses in cultured Müller glia and microglia in response to elevated hydrostatic pressure. Based on our previous and these findings, we propose development of AAV2-hAIBP based therapy to reduce retinal neuroinflammation and provide effective neuroprotection to glaucoma patients receiving standard-of-care IOP lowering treatment. We propose the following milestone-driven Specific Aims: (1) Optimize AAV2-hAIBP and define AIBP distribution and target engagement in retina; (2) Characterize the in vivo efficacy and non-GLP toxicology of AAV2-hAIBP; and (3) Conduct IND-enabling studies and obtain FDA approval for first-in-human trial. The project will combine expertise and resources from University of California, San Diego, RAFT Pharmaceuticals, and the NIH Blueprint Neurotherapeutics Network – Biologic. Our proposed studies will develop novel gene therapy to reduce retinal neuroinflammation and mitochondrial dysfunction and provide effective neuroprotection to glaucoma patients.
青光眼是全世界失明的主要原因。新出现的证据表明,神经胶质炎症

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WONKYU JU其他文献

WONKYU JU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WONKYU JU', 18)}}的其他基金

AAV-AIBP Therapy for Alzheimer's Disease
AAV-AIBP 治疗阿尔茨海默病
  • 批准号:
    10708176
  • 财政年份:
    2022
  • 资助金额:
    $ 77.68万
  • 项目类别:
AAV-AIBP Therapy for Alzheimer's Disease
AAV-AIBP 治疗阿尔茨海默病
  • 批准号:
    10604136
  • 财政年份:
    2022
  • 资助金额:
    $ 77.68万
  • 项目类别:
Mitochondrial Protection in Glaucomatous Optic Neuropathy
青光眼视神经病变中的线粒体保护
  • 批准号:
    10667427
  • 财政年份:
    2020
  • 资助金额:
    $ 77.68万
  • 项目类别:
Mitochondrial Protection in Glaucomatous Optic Neuropathy
青光眼视神经病变中的线粒体保护
  • 批准号:
    10376972
  • 财政年份:
    2020
  • 资助金额:
    $ 77.68万
  • 项目类别:
Mitochondrial Protection in Glaucomatous Optic Neuropathy
青光眼视神经病变中的线粒体保护
  • 批准号:
    10441589
  • 财政年份:
    2020
  • 资助金额:
    $ 77.68万
  • 项目类别:
Mitochondrial Protection in Glaucomatous Optic Neuropathy
青光眼视神经病变中的线粒体保护
  • 批准号:
    10241476
  • 财政年份:
    2020
  • 资助金额:
    $ 77.68万
  • 项目类别:
Mitochondrial Protection in Glaucomatous Optic Neuropathy
青光眼视神经病变中的线粒体保护
  • 批准号:
    10610198
  • 财政年份:
    2020
  • 资助金额:
    $ 77.68万
  • 项目类别:
Mitochondrial Protection in Glaucomatous Optic Neuropathy
青光眼视神经病变中的线粒体保护
  • 批准号:
    10035019
  • 财政年份:
    2020
  • 资助金额:
    $ 77.68万
  • 项目类别:
Mitochondrial Protection in Glaucomatous Optic Neuropathy
青光眼视神经病变中的线粒体保护
  • 批准号:
    10711446
  • 财政年份:
    2020
  • 资助金额:
    $ 77.68万
  • 项目类别:
Mitochondrial Dysfunction in Glaucomatous Optic Neuropathy
青光眼视神经病变中的线粒体功能障碍
  • 批准号:
    9464735
  • 财政年份:
    2009
  • 资助金额:
    $ 77.68万
  • 项目类别:

相似海外基金

ATP Binding Cassette Transporters in Health and Disease
健康和疾病中的 ATP 结合盒转运蛋白
  • 批准号:
    10390366
  • 财政年份:
    2021
  • 资助金额:
    $ 77.68万
  • 项目类别:
ATP Binding Cassette Transporters in Health and Disease
健康和疾病中的 ATP 结合盒转运蛋白
  • 批准号:
    10237095
  • 财政年份:
    2021
  • 资助金额:
    $ 77.68万
  • 项目类别:
ATP Binding Cassette Transporters in Health and Disease
健康和疾病中的 ATP 结合盒转运蛋白
  • 批准号:
    10552563
  • 财政年份:
    2021
  • 资助金额:
    $ 77.68万
  • 项目类别:
Photosensitizing Nanoconstructs for Regulation of ATP-Binding Cassette Transporters in the Brain
用于调节大脑中 ATP 结合盒转运蛋白的光敏纳米结构
  • 批准号:
    2030253
  • 财政年份:
    2020
  • 资助金额:
    $ 77.68万
  • 项目类别:
    Standard Grant
Structural and functional studies of iron uptake ATP-binding cassette transporters (ABC transporters) in Gram-negative bacteria
革兰氏阴性菌中铁摄取 ATP 结合盒转运蛋白(ABC 转运蛋白)的结构和功能研究
  • 批准号:
    20K22561
  • 财政年份:
    2020
  • 资助金额:
    $ 77.68万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Investigating the mechanism of polysaccharide recognition and export by bacterial ATP-binding cassette transporters
研究细菌 ATP 结合盒转运蛋白识别和输出多糖的机制
  • 批准号:
    489384-2016
  • 财政年份:
    2018
  • 资助金额:
    $ 77.68万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Investigating the mechanism of polysaccharide recognition and export by bacterial ATP-binding cassette transporters
研究细菌 ATP 结合盒转运蛋白识别和输出多糖的机制
  • 批准号:
    489384-2016
  • 财政年份:
    2017
  • 资助金额:
    $ 77.68万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Investigating the mechanism of polysaccharide recognition and export by bacterial ATP-binding cassette transporters
研究细菌 ATP 结合盒转运蛋白识别和输出多糖的机制
  • 批准号:
    489384-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 77.68万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
The Mechanism of ATP Binding Cassette Transporters
ATP 结合盒转运蛋白的机制
  • 批准号:
    318360
  • 财政年份:
    2014
  • 资助金额:
    $ 77.68万
  • 项目类别:
    Fellowship Programs
Heat shock protein 27 attenuates foam cell formation by enhancing cholesterol efflux via the ATP-binding cassette transporters A1
热休克蛋白 27 通过 ATP 结合盒转运蛋白 A1 增强胆固醇流出,从而减弱泡沫细胞形成
  • 批准号:
    304334
  • 财政年份:
    2014
  • 资助金额:
    $ 77.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了